[HTML][HTML] Molecular mechanism of action and potential biomarkers of growth inhibition of synergistic combination of afatinib and dasatinib against gefitinib-resistant non …
M Wang, AYC Chang - Oncotarget, 2018 - ncbi.nlm.nih.gov
Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is the first choice of
treatment for advanced non-small cell lung cancer (NSCLC) patients harbouring activating …
treatment for advanced non-small cell lung cancer (NSCLC) patients harbouring activating …
[HTML][HTML] Molecular mechanism of action and potential biomarkers of growth inhibition of synergistic combination of afatinib and dasatinib against gefitinib-resistant non …
M Wang, AY Chang - Oncotarget, 2018 - oncotarget.com
Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is the first choice of
treatment for advanced non-small cell lung cancer (NSCLC) patients harbouring activating …
treatment for advanced non-small cell lung cancer (NSCLC) patients harbouring activating …
Molecular mechanism of action and potential biomarkers of growth inhibition of synergistic combination of afatinib and dasatinib against gefitinib-resistant non-small …
M Wang - Oncotarget, 2018 - europepmc.org
Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is the first choice of
treatment for advanced non-small cell lung cancer (NSCLC) patients harbouring activating …
treatment for advanced non-small cell lung cancer (NSCLC) patients harbouring activating …
[PDF][PDF] Molecular mechanism of action and potential biomarkers of growth inhibition of synergistic combination of afatinib and dasatinib against gefitinib-resistant non …
M Wang, AYC Chang - pdfs.semanticscholar.org
Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is the first choice of
treatment for advanced non-small cell lung cancer (NSCLC) patients harbouring activating …
treatment for advanced non-small cell lung cancer (NSCLC) patients harbouring activating …
Molecular mechanism of action and potential biomarkers of growth inhibition of synergistic combination of afatinib and dasatinib against gefitinib-resistant non-small …
M Wang, AYC Chang - Oncotarget, 2018 - pure.johnshopkins.edu
Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is the first choice of
treatment for advanced non-small cell lung cancer (NSCLC) patients harbouring activating …
treatment for advanced non-small cell lung cancer (NSCLC) patients harbouring activating …
Molecular mechanism of action and potential biomarkers of growth inhibition of synergistic combination of afatinib and dasatinib against gefitinib-resistant non-small …
M Wang, AYC Chang - Oncotarget, 2018 - pubmed.ncbi.nlm.nih.gov
Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is the first choice of
treatment for advanced non-small cell lung cancer (NSCLC) patients harbouring activating …
treatment for advanced non-small cell lung cancer (NSCLC) patients harbouring activating …
Molecular mechanism of action and potential biomarkers of growth inhibition of synergistic combination of afatinib and dasatinib against gefitinib-resistant non-small …
M Wang, AY Chang - Oncotarget, 2018 - oncotarget.com
Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is the first choice of
treatment for advanced non-small cell lung cancer (NSCLC) patients harbouring activating …
treatment for advanced non-small cell lung cancer (NSCLC) patients harbouring activating …
Molecular mechanism of action and potential biomarkers of growth inhibition of synergistic combination of afatinib and dasatinib against gefitinib-resistant non-small …
M Wang - Oncotarget, 2018 - europepmc.org
Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is the first choice of
treatment for advanced non-small cell lung cancer (NSCLC) patients harbouring activating …
treatment for advanced non-small cell lung cancer (NSCLC) patients harbouring activating …